- Home
- COLL vs EYPT Comparison
COLL vs EYPT Comparison
Compare COLL & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COLL | EYPT |
|---|---|---|
| Founded | 2002 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2015 | 2005 |
Fundamental Metrics
Financial Performance| Metric | COLL | EYPT |
|---|---|---|
| Price | $36.25 | $13.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $51.40 | $31.80 |
| AVG Volume (30 Days) | 360.6K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $780,567,000.00 | $7,539,000.00 |
| Revenue This Year | $8.01 | N/A |
| Revenue Next Year | N/A | $3,115.57 |
| P/E Ratio | $87.10 | ★ N/A |
| Revenue Growth | ★ 23.62 | N/A |
| 52 Week Low | $29.19 | $8.96 |
| 52 Week High | $50.79 | $19.11 |
Technical Indicators
Market Signals| Indicator | COLL | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 60.89 | 54.50 |
| Support Level | $33.80 | $13.61 |
| Resistance Level | $48.74 | $14.82 |
| Average True Range (ATR) | 1.30 | 0.80 |
| MACD | 0.27 | 0.18 |
| Stochastic Oscillator | 87.86 | 64.85 |
Price Performance
Historical ComparisonAbout COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.